• Long-lasting responses with Veyonda + low-dose radiotherapy in late-stage prostate cancer
• High proportion of disease control following a single, short course of treatment
• Complete resolution of pain achieved in some patients
SYDNEY, 2 May 2019: Noxopharm (ASX:NOX) (‘Noxopharm’ or the ‘Company’) is pleased to announce the 6-month interim results from the dose-escalation arm of the DARRT-1 (Direct and Abscopal Response to Radio- Therapy) study.
For further information please download pdf attached:
Download this document
